Use of genetic mutations for prediction of resistance to pyrazinamide in M. tuberculosis strains
Pyrazinamide (PZA) is a prodrug that is converted to the active compound pyrazinoic acid by the pyrazinamidase enzyme (encoded by the pncA gene in Mycobacterium tuberculosis) at low pH. The phenotypic approach for testing pyrazinamide sensitivity is technically demanding (often associated with poorl...
Main Authors: | Daniela M Cirillo, Paolo Miotto, Stefan Niemann |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2015-01-01
|
Series: | International Journal of Mycobacteriology |
Subjects: | |
Online Access: | http://www.ijmyco.org/article.asp?issn=2212-5531;year=2015;volume=4;issue=5;spage=42;epage=43;aulast=Cirillo;type=0 |
Similar Items
-
Structural Dynamics Behind Clinical Mutants of PncA-Asp12Ala, Pro54Leu, and His57Pro of Mycobacterium tuberculosis Associated With Pyrazinamide Resistance
by: Aamir Mehmood, et al.
Published: (2019-12-01) -
Pyrazinamide Resistance and pncA Mutation Profiles in Multidrug Resistant Mycobacterium Tuberculosis
by: Shi D, et al.
Published: (2022-08-01) -
The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide
by: Géraldine Daneau, et al.
Published: (2016-01-01) -
Ability of the MeltPro MTB/PZA Assay to Detect Susceptibility to Pyrazinamide in Rifampin-Resistant Tuberculosis Patients
by: Rong Li, et al.
Published: (2023-06-01) -
Marine Natural Products and Drug Resistance in Latent Tuberculosis
by: Muhammad Tahir Khan, et al.
Published: (2019-09-01)